Angiodynamics, Inc. Reports Earnings Results for the Second Quarter Ended November 30, 2020
January 07, 2021 at 05:30 pm IST
Share
AngioDynamics, Inc. announced earnings results for the second quarter ended November 30, 2020. For the second quarter, the company announced sales was USD 72.770 million compared to USD 70.003 million a year ago. Operating loss was USD 4.836 million compared to USD 3.423 million a year ago. Net loss was USD 4.268 million compared to USD 2.736 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.07 a year ago. For the half year, sales was USD 142.986 million compared to USD 136.045 million a year ago. Operating loss was USD 9.958 million compared to USD 4.251 million a year ago. Net loss was USD 8.536 million compared to USD 4.011 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.11 a year ago.
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
ANGIODYNAMICS, INC. 
